Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RPSA as a Potential Prognostic Biomarker of PDAC

NCT04575363 is registered in ClinicalTrials.gov with CHU de Reims as lead sponsor.

NCT NCT04575363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RPSA as a Potential Prognostic Biomarker of PDAC
Lead sponsor
CHU de Reims
Phase
Not applicable
Overall status
Recruiting
Start date
October 18, 2021
Completion date
October 18, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac)